1
|
Makris G, Kayhan S, Kreuzer M, Rüfenacht V, Faccin E, Underhaug J, Diez-Fernandez C, Knobel PA, Poms M, Gougeard N, Rubio V, Martinez A, Pruschy M, Häberle J. Impact of small molecule-mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism. Cancer Commun (Lond) 2023; 43:508-512. [PMID: 36708276 PMCID: PMC10091103 DOI: 10.1002/cac2.12402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 11/17/2022] [Accepted: 12/21/2022] [Indexed: 01/29/2023] Open
Affiliation(s)
- Georgios Makris
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.,Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Semih Kayhan
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Marvin Kreuzer
- Department of Radiation Oncology, Laboratory for Applied Radiobiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Véronique Rüfenacht
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Erica Faccin
- Department of Radiation Oncology, Laboratory for Applied Radiobiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Jarl Underhaug
- Department of Biomedicine, University of Bergen, Bergen, Norway.,Department of Chemistry, University of Bergen, Bergen, Norway
| | - Carmen Diez-Fernandez
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.,NUVISAN GmbH, Neu-Ulm, Bavaria, Germany
| | - Philip A Knobel
- Department of Radiation Oncology, Laboratory for Applied Radiobiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.,CDR Life Inc., Schlieren, Zurich, Switzerland
| | - Martin Poms
- Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Nadine Gougeard
- Instituto de Biomedicina de Valencia (IBV-CSIC), CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain
| | - Vicente Rubio
- Instituto de Biomedicina de Valencia (IBV-CSIC), CIBER de Enfermedades Raras (CIBERER-ISCIII), Valencia, Spain
| | - Aurora Martinez
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Martin Pruschy
- Department of Radiation Oncology, Laboratory for Applied Radiobiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Johannes Häberle
- Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
| |
Collapse
|
2
|
Deycmar S, Faccin E, Kazimova T, Knobel PA, Telarovic I, Tschanz F, Waller V, Winkler R, Yong C, Zingariello D, Pruschy M. The relative biological effectiveness of proton irradiation in dependence of DNA damage repair. Br J Radiol 2019; 93:20190494. [PMID: 31687835 DOI: 10.1259/bjr.20190494] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Clinical parameters and empirical evidence are the primary determinants for current treatment planning in radiation oncology. Personalized medicine in radiation oncology is only at the very beginning to take the genetic background of a tumor entity into consideration to define an individual treatment regimen, the total dose or the combination with a specific anticancer agent. Likewise, stratification of patients towards proton radiotherapy is linked to its physical advantageous energy deposition at the tumor site with minimal healthy tissue being co-irradiated distal to the target volume. Hence, the fact that photon and proton irradiation also induce different qualities of DNA damages, which require differential DNA damage repair mechanisms has been completely neglected so far. These subtle differences could be efficiently exploited in a personalized treatment approach and could be integrated into personalized treatment planning. A differential requirement of the two major DNA double-strand break repair pathways, homologous recombination and non-homologous end joining, was recently identified in response to proton and photon irradiation, respectively, and subsequently influence the mode of ionizing radiation-induced cell death and susceptibility of tumor cells with defects in DNA repair machineries to either quality of ionizing radiation.This review focuses on the differential DNA-damage responses and subsequent biological processes induced by photon and proton irradiation in dependence of the genetic background and discusses their impact on the unicellular level and in the tumor microenvironment and their implications for combined treatment modalities.
Collapse
Affiliation(s)
- Simon Deycmar
- Laboratory for Applied Radiobiology Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Gödde S, Dinges H, Müller-Ladner U, Renner C. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2007; 8:R171. [PMID: 17105646 PMCID: PMC1794515 DOI: 10.1186/ar2080] [Citation(s) in RCA: 154] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2006] [Revised: 10/02/2006] [Accepted: 11/14/2006] [Indexed: 12/04/2022] Open
Abstract
Fibroblast activation protein (FAP), as described so far, is a type II cell surface serine protease expressed by fibroblastic cells in areas of active tissue remodelling such as tumour stroma or healing wounds. We investigated the expression of FAP by fibroblast-like synoviocytes (FLSs) and compared the synovial expression pattern in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Synovial tissue from diseased joints of 20 patients, 10 patients with refractory RA and 10 patients with end-stage OA, was collected during routine surgery. As a result, FLSs from intensively inflamed synovial tissues of refractory RA expressed FAP at high density. Moreover, FAP expression was co-localised with matrix metalloproteinases (MMP-1 and MMP-13) and CD44 splice variants v3 and v7/8 known to play a major role in the concert of extracellular matrix degradation. The pattern of signals appeared to constitute a characteristic feature of FLSs involved in rheumatoid arthritic joint-destructive processes. These FAP-expressing FLSs with a phenotype of smooth muscle actin-positive myofibroblasts were located in the lining layer of the synovium and differ distinctly from Thy-1-expressing and non-proliferating fibroblasts of the articular matrix. The intensity of FAP-specific staining in synovial tissue from patients with RA was found to be different when compared with end-stage OA. Because expression of FAP by RA FLSs has not been described before, the findings of this study highlight a novel element in cartilage and bone destruction of arthritic joints. Moreover, the specific expression pattern qualifies FAP as a therapeutic target for inhibiting the destructive potential of fibroblast-like synovial cells.
Collapse
Affiliation(s)
- Stefan Bauer
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Michael C Jendro
- Med. Department I, Universität des Saarlandes, Kirrbergstrasse, 66421 Homburg/Saar, Germany
| | - Andreas Wadle
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Sascha Kleber
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Frank Stenner
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Robert Dinser
- Department of Internal Medicine and Rheumatology, University of Giessen and Kerckhoff-Clinic, Benekestrasse 2–8, 61231 Bad Nauheim, Germany
| | - Anja Reich
- Med. Department I, Universität des Saarlandes, Kirrbergstrasse, 66421 Homburg/Saar, Germany
| | - Erica Faccin
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Stefan Gödde
- Orthopedic Department, Universität des Saarlandes, Kirrbergstrasse, 66421 Homburg/Saar, Germany
| | - Harald Dinges
- Orthopedic Clinic, Westpfalz-Klinikum, Im Flur 1, 66869 Kusel, Germany
| | - Ulf Müller-Ladner
- Department of Internal Medicine and Rheumatology, University of Giessen and Kerckhoff-Clinic, Benekestrasse 2–8, 61231 Bad Nauheim, Germany
| | - Christoph Renner
- Oncology Department, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| |
Collapse
|